A case of cryopyrin-associated periodic fever syndrome during canakinumab administration complicated by inflammatory bowel disease
| Autor: | Yoshifumi Kawano, Yukiko Nonaka, Hiroyuki Imanaka, Tomohiro Kubota, Syuji Takei, Yuichi Yamasaki |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
medicine.medical_specialty
Hearing Loss Sensorineural Interleukin-1beta Perforation (oil well) Arthritis Antibodies Monoclonal Humanized Inflammatory bowel disease 03 medical and health sciences 0302 clinical medicine Rheumatology NLR Family Pyrin Domain-Containing 3 Protein medicine Humans 030212 general & internal medicine 030203 arthritis & rheumatology business.industry Aseptic meningitis General Medicine Inflammatory Bowel Diseases medicine.disease Dermatology Rash Cryopyrin-Associated Periodic Syndromes Infliximab Canakinumab Female medicine.symptom business Periodic fever syndrome medicine.drug |
| Zdroj: | Clinical Rheumatology. 40:393-397 |
| ISSN: | 1434-9949 0770-3198 |
| Popis: | Cryopyrin-associated periodic fever syndrome (CAPS) is a highly debilitating disorder, which is characterized by unregulated interleukin-1β production driven by autosomal dominantly inherited mutations in the NLRP3 gene. Patients with CAPS often present with early-onset episodes of fever and rash. These patients also present with variable systemic signs and symptoms, such as arthritis, sensorineural hearing loss, chronic aseptic meningitis, and skeletal abnormalities, but minimal gastrointestinal symptoms. Recently, effective therapies for CAPS targeted against interleukin-1 have become available. We report a case of a young Japanese woman with CAPS who developed inflammatory bowel disease during canakinumab therapy. The patient had colostomy after intestinal perforation and changed canakinumab to infliximab. To the best of our knowledge, this is the first report of a case of inflammatory bowel disease secondary to CAPS complicated by gastrointestinal symptoms and arthritis which canakinumab could not control. Patients with CAPS who have symptoms that cannot be controlled by canakinumab should be considered for possible co-morbidities. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink